|
GB9921751D0
|
|
Method of protecting proteins and amino acids from microbial degradation
|
|
GB9921426D0
|
|
Production of bi-specific particles
|
|
GB9909345D0
|
|
Pig breeding
|
|
GB9816033D0
|
|
Sequence
|
|
AU5492998A
|
|
Immunomodulating properties, amino acid and nucleotide sequence of colostrum derived growth factor
|
|
GB9705759D0
|
|
Use of lectins
|
|
GB9701325D0
|
|
Sequence
|
|
GB9701179D0
|
|
Sequence
|
|
GB9700871D0
|
|
Sequence
|
|
GB9700730D0
|
|
Sequence
|
|
GB9514835D0
|
|
Polypeptide
|
|
GB9514580D0
|
|
Polypeptide
|
|
US6121002A
|
|
Method to detect bone and other connective tissue disorders in humans and animals
|
|
US5541188A
|
|
Therapeutic applications of beta-adrenergic agonists
|
|
US5530029A
|
|
Therapeutic applications of clenbuterol
|
|
WO9406015A1
|
|
Method to monitor drug therapy and assess metastasis
|
|
GB9217669D0
|
|
The therapeutic use of b-agonists in the treatment of amelioration of symptoms of muscle wasting diseases in man or animals
|
|
GB9215763D0
|
|
The therapeutic use of b-agonists in the treatment of amelioration of symptoms of muscle wasting diseases in man or animals
|
|
GB9027185D0
|
|
Probiosis
|
|
GB9024279D0
|
|
Carrier system
|
